Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

19.2%

55 terminated/withdrawn out of 287 trials

Success Rate

74.2%

-12.3% vs industry average

Late-Stage Pipeline

31%

89 trials in Phase 3/4

Results Transparency

80%

127 of 158 completed trials have results

Key Signals

37 recruiting127 with results36 terminated19 withdrawn

Enrollment Performance

Analytics

Phase 2

101(39.3%)

Phase 3

74(28.8%)

Phase 1

64(24.9%)

Phase 4

15(5.8%)

N/A

2(0.8%)

Early Phase 1

1(0.4%)

257Total

Phase 2(101)

Phase 3(74)

Phase 1(64)

Phase 4(15)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (287)

Showing 20 of 287 trials

NCT07233239Phase 1Recruiting

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

Role: lead

NCT04217278Phase 2Active Not Recruiting

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Role: collaborator

NCT05629702Phase 2Recruiting

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids

Role: collaborator

NCT07102381Phase 2Recruiting

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Role: lead

NCT07459634Phase 2Not Yet Recruiting

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Role: lead

NCT05864846Phase 4Completed

A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex

Role: lead

NCT03878199Phase 1Terminated

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Role: collaborator

NCT05869773Phase 4Completed

A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy

Role: lead

NCT05557045Phase 1Recruiting

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Role: lead

NCT05044819Phase 4Active Not Recruiting

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Role: lead

NCT07377539Phase 1Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants

Role: lead

NCT05152147Phase 3Active Not Recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Role: lead

NCT07533942Phase 2Not Yet Recruiting

A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

Role: lead

NCT05580562Phase 3Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Role: lead

NCT03572764Phase 1Active Not Recruiting

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

Role: collaborator

NCT05099666Phase 1Active Not Recruiting

Lurbinectedin + Doxorubicin In Leiomyosarcoma

Role: collaborator

NCT06113237Recruiting

Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy

Role: lead

NCT06695845Phase 2Recruiting

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Role: lead

NCT06738368Phase 2Recruiting

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Role: collaborator

NCT05918640Phase 1Recruiting

Lurbinectedin in FET-Fused Tumors

Role: collaborator